inclusion criteria: to be eligible to participate in the study, patients must meet the following criteria: ability to provide written or remote informed consent (telephone and docusign) ability to comply with study requirements, men or women 18 to 85 years of age, inclusive current diagnosis of an initial occurrence of non-severe, non-complicated cov+ infection as defined by: - presence covid-19 in the saliva using poc qrt- pcr assay.. - management in an outpatient (i.e., non-hospital) or inpatient setting not on a ventilator. - alert and awake - able to chew the study drug completely. - women should fulfill one of the following criteria: - answer in the affirmative that "they are not or could not be pregnant" - post-menopausal; either amenorrhea ≥12 months or follicle stimulating hormone >20 miu/ml - surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation. - women of childbearing potential participating in heterosexual sexual relations must be willing to use adequate contraception from screening through the 21 day visit, per section 10.2.

inclusion criteria: to be eligible to participate in the study, patients must meet the following criteria: ability to provide written or remote informed consent (telephone and docusign) ability to comply with study requirements, men or women 18 to 85 years of age, inclusive current diagnosis of an initial occurrence of non-severe, non-complicated cov+ infection as defined by: - presence covid-19 in the saliva using poc qrt- pcr assay.. - management in an outpatient (i.e., non-hospital) or inpatient setting not on a ventilator. - alert and awake - able to chew the study drug completely. - women should fulfill one of the following criteria: - answer in the affirmative that "they are not or could not be pregnant" - post-menopausal; either amenorrhea ≥12 months or follicle stimulating hormone >20 miu/ml - surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation. - women of childbearing potential participating in heterosexual sexual relations must be willing to use adequate contraception from screening through the 21 day visit, per section 10.2.